Gilead Sciences — Aug 7, 2025 release

Guidance and Outlook For the full-year, Gilead expects: (in millions, except per share amounts) August 7, 2025 Guidance Low End High End Comparison to Prior Guidance Product sales $ 28,300  $ 28,700  Previously $28,200 to $28,600 Product sales excluding Veklury $ 27,300  $ 27,700  Previously $26,800 to $27,200 Veklury $ 1,000  $ 1,000  Previously $1,400 Diluted EPS $ 5.85  $ 6.15  Previously $5.65 to $6.05 Non-GAAP diluted EPS $ 7.95  $ 8.25  Previously $7.70 to $8.10 August 7, 2025 3      Additional information and a reconciliation between GAAP and non-GAAP financial information for the 2025 guidance is provided in the accompanying tables. The financial guidance is subject to a number of risks and uncertainties. See the Forward-Looking Statements section below. Key Updates Since Our Last Quarterly Release Virology • Received U.S. Food and Drug Administration (“FDA”) approval for Yeztugo® (lenacapavir) for pre-exposure prophylaxis (“PrEP”) to reduce the risk of sexually acquired HIV-1 in adults and adolescents weighing at least 35kg. Yeztugo is the first and only twice-yearly HIV PrEP option available in the United States. • Received a positive opinion under accelerated review from the European Medicines Agency’s Committee for Medicinal Products for Human Use recommending lenacapavir for use as PrEP to reduce the risk of sexually acquired HIV-1 in adults and adolescents with increased HIV-1 acquisition risk. The recommendation will now be reviewed by the European Commission. Lenacapavir for HIV PrEP is not approved for use outside of the United Sta